CRVSCorvus Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Corvus Pharmaceuticals, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRVS본 종목 | $1.1B#7 | — | 4.7x#10 | — | — | 75.4%#3 | — | -6.8%#5 | — | — | 116.1%#3 | — |
| SPTX | $1.2B#2 | — | 2.8x#8 | — | — | — | — | 0.0%#4 | — | — | — | — |
| ANRO | $1.2B#1 | — | 5.5x#12 | — | — | -2.9%#5 | — | -28.8%#8 | — | — | 692.2%#1 | — |
| MNKD | $1.2B#3 | — | — | 3.3x#3 | 22.2%#4 | -78.7%#11 | 11.1%#2 | — | 2283.8%#1 | — | -33.1%#12 | — |
| MLTX | $1.1B#8 | — | 2.5x#6 | — | — | -91.1%#13 | — | -53.1%#12 | -491.6%#7 | — | -75.9%#14 | — |
| JBIO | $1.1B#5 | — | 2.5x#7 | — | — | -83.0%#12 | — | -29.0%#10 | — | — | 144.5%#2 | — |
| SVRA | $1.1B#4 | — | 7.6x#13 | 4253.1x#9 | — | -23.9%#7 | -48072.8%#9 | -82.7%#13 | -93.6%#6 | — | 48.2%#6 | — |
| OBX | $1.1B#6 | — | — | — | — | -21.1%#6 | — | — | — | — | — | — |
| AMPH | $1.0B#10 | 14.2x#1 | 2.3x#5 | 1.4x#2 | -1.7%#6 | -38.5%#8 | 19.5%#1 | 22.0%#2 | 13.2%#2 | 5#1 | -11.2%#10 | — |
| KURA | $1.0B#9 | — | 21.3x#14 | 15.3x#5 | 25.2%#3 | -60.2%#9 | -449.9%#6 | -575.4%#14 | — | — | 43.1%#7 | — |
| JANX | $1.0B#11 | — | 1.1x#1 | 101.7x#8 | -5.6%#7 | -64.7%#10 | -1576.7%#8 | -12.2%#6 | — | — | -29.1%#11 | — |
| PCRX | $991M#12 | 71.1x#3 | 1.5x#2 | 1.4x#1 | 3.6%#5 | 107.0%#2 | 2.6%#3 | 1.0%#3 | 1.0%#3 | — | -4.5%#9 | — |
| LXRX | $901M#13 | — | 5.2x#11 | 18.1x#6 | 60.2%#2 | 74.9%#4 | -98.2%#5 | -28.8%#9 | -26.4%#5 | — | 84.9%#4 | — |
| AVTX | $897M#14 | — | 2.0x#4 | 15211.8x#10 | -86.6%#9 | -122.8%#15 | -123601.7%#10 | -17.4%#7 | -19.3%#4 | — | 48.2%#5 | — |
| WVE | $897M#15 | — | 2.0x#3 | 21.0x#7 | -60.5%#8 | -110.7%#14 | -504.1%#7 | -45.1%#11 | — | — | -33.1%#13 | — |
| TBPH | $884M#16 | 16.4x#2 | 3.1x#9 | 8.2x#4 | 66.9%#1 | 287.7%#1 | -3.4%#4 | 36.6%#1 | — | — | 21.3%#8 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice